文献速递血栓与止血

即用型冷冻保存血小板用于检测HIT和VITT抗体

Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies.
PubMed 文献 · Blood · 2022-01-01

研究优化血小板冷冻保存条件并建立基于凝血酶敏感蛋白-1释放的ELISA功能试验,用数月龄冷冻血小板检测HIT和VITT抗体;HIT和自发性HIT样本经PF4或肝素处理冷冻血小板后TSP1释放显著高于缺乏血小板活化抗体的疑似HIT样本,4例VITT样本仅激活PF4处理血小板。

要点

  • 冷冻保存血小板经PF4或肝素处理后可被HIT抗体激活并释放TSP1。
  • HIT和自发性HIT样本的TSP1释放显著高于缺乏血小板活化抗体的疑似HIT样本。
  • 4例VITT样本仅激活PF4处理、而非肝素处理的冷冻保存血小板。

核心结论

  • 优化冷冻保存条件可延长血小板活性数月,并建立简单的TSP1释放ELISA功能试验,用于检测HIT和VITT抗体。

研究设计与样本

  • 研究优化血小板冷冻保存条件,以可控冷却速率冻存血小板,并用数月龄冷冻保存血小板进行TSP1释放试验(TRA)评估HIT和VITT抗体。

主要发现

  • HIT和自发性HIT患者样本经PF4处理(PF4-TRA)和肝素处理冷冻保存血小板后,TSP1释放显著高于缺乏血小板活化抗体的疑似HIT患者样本。
  • 缺乏血小板活化抗体的疑似HIT组中包括数例PF4-聚阴离子ELISA强阳性但无血小板活化抗体的患者。
  • 4例VITT患者样本在TRA中激活PF4处理、而非肝素处理的冷冻保存血小板。

临床怎么用

  • 作者认为这些发现有可能改变HIT和VITT的检测模式,使分散、技术简单的功能检测可用于院内快速准确诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin-induced thrombocytopenia (HIT) is suspected much more often than it is confirmed. Technically simple platelet factor 4 (PF4)-polyanion enzyme-linked immunosorbent assays (ELISAs) are sensitive but nonspecific. In contrast, accurate functional tests such as the serotonin release assay, heparin-induced platelet activation assay, and PF4-dependent P-selectin expression assay require fresh platelets and have complex assay end points, limiting their availability to specialized reference laboratories. To enable broad deployment of functional testing, we sought to extend platelet viability significantly by optimizing storage conditions and developed a simple functional assay end point by measuring the release of a platelet α-granule protein, thrombospondin-1 (TSP1), in an ELISA format. Platelet cryopreservation conditions were optimized by freezing platelets at controlled cooling rates that preserve activatability. Several-month-old cryopreserved platelets were treated with PF4 or heparin and were evaluated for their ability to be activated by HIT and vaccine-induced immune thrombotic thrombocytopenia (VITT) antibodies in the TSP1 release assay (TRA). HIT and spontaneous HIT patient samples induced significantly higher TSP1 release using both PF4-treated (PF4-TRA) and heparin-treated cryopreserved platelets relative to samples from patients suspected of HIT who lacked platelet-activating antibodies. This latter group included several patients that tested strongly positive in PF4-polyanion ELISA but were not platelet-activating. Four VITT patient samples tested in the TRA activated PF4-treated, but not heparin-treated, cryopreserved platelets, consistent with recent data suggesting the requirement for PF4-treated platelets for VITT antibody detection. These findings have the potential to transform the testing paradigm in HIT and VITT, making decentralized, technically simple functional testing available for rapid and accurate in-hospital diagnosis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kanack AJ, Jones CG, Singh B, et al. Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies. Blood. 2022. PMID: 35998675. doi:10.1182/blood.2022017283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。